Multinational biotechnology company Biogen has confirmed it will shut down Biogen Digital Health, a global unit of the biotech company, and pull out of a study with Apple. Still, the company says it will continue to integrate some digital capabilities into other functions of its business.
"As our CEO Chris Viehbacher mentioned when he announced Fit for Growth, part of the initiative is removing...
Digital therapeutics company Twill, previously known as Happify Health, is partnering with e-Psychiatry to offer virtual access to psychiatrists, psychologists and therapists.
Conn.-based e-Psychiatry's services will be offered as an element of Twill's Sequences, a platform made up of digital therapeutics, community groups and coaching aimed at mental health conditions and pregnancy.
Twill is...
Digital therapeutic maker Happify Health is partnering with neuroscience-focused pharma company Biogen on a digital engagement and education platform for multiple sclerosis.
The product will include Happify's community for people living with MS, as well as access to neurology providers like doctors and nurses, mental health professionals, dietitians and rehabilitation professionals. Biogen will...
Prescription digital therapeutics startup MedRhythms has entered into a licensing agreement with Biogen to develop and commercialize its MR-004 product, which aims to improve mobility for people with multiple sclerosis (MS).
Under the deal, MedRhythms would receive a $3 million upfront payment from Biogen, with the potential to earn up to $117.5 million if certain development and commercial...
Apple is looking to use digital biomarkers to help detect depression and early-stage cognitive decline, according to a new report out of The Wall Street Journal.
The end goal, according to the Journal, is to create a new Apple feature that would tell users if there was a potential mental illness. Data collected regarding a users’ mobility, physical activity, sleep pattern could be included in...
Biogen has announced a new multiyear research study on cognitive decline that will be conducted using the Apple Watch and iPhone.
The observational study is being conducted in collaboration with Apple, according to the announcement, and is set to kick off later this year. The project's primary goal is to establish digital biomarkers for monitoring long-term cognitive performance and to spot early...
About the author: Naomi Fried, PhD (@NaomiFried), is the CEO of Health Innovation Strategies, which provides digital health strategy and innovation infrastructure consulting to healthcare stakeholders including pharma companies and providers. Her previous positions include the first Chief Innovation Officer at Boston Children’s Hospital, Biogen’s VP of Innovation and External Partnerships, and VP...
Boston-based patient network PatientsLikeMe announced two pieces of pharma news this week: a five-year research collaboration deal with AstraZeneca and the results of a multiple sclerosis wearable study conducted in collaboration with Biogen.
The PatientsLikeMe-AstraZeneca deal is similar to one the company struck with Genentech last Spring. AstraZeneca will have full access to PatientsLikeMe's...
